Role of N-Acetyltransferase Phenotype in Human Susceptibility To Bladder Carcinogenic Arylamines
Hans Wolf, Gerald M. Lower, G T Bryan
Abstract
Hans Wolf, Gerald M. Lower, G T Bryan
Abstract
N-acetyltransferase activity is species-specific and in animal experiments a determinant of the susceptibility of each species to arylamine bladder carcinogens. The effect of N-acetylation is that of inactivation. In humans, N-acetyltransferase activity is also genetically determined so that two N-acetyltransferase phenotypes exist, a rapid acetylator phenotype and a slow acetylator phenotype. N-acetyltransferase phenotype was determined in 71 bladder cancer patients and in 74 control subjects from Copenhagen. The distribution of the slow acetylator phenotype among the bladder cancer patients was 65% in control to 51% among the control subjects, indicating that the N-acetyltransferase phenotype also in humans may be a determinant of the susceptibility of each individual to arylamine carcinogens. In addition, this finding indicates that carcinogenic arylamines also play a role in bladder carcinogenesis in Copenhagen. Such studies may identify risk groups in a population and may reveal geographical areas with arylamine induced bladder cancer.
OpenAlex reports 40 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
N-acetyltransferase activity is species-specific and in animal experiments a determinant of the susceptibility of each species to arylamine bladder carcinogens. The effect of N-acetylation is that of inactivation. In humans, N-acetyltransferase activity is also genetically determined so that two N-acetyltransferase phenotypes exist, a rapid acetylator phenotype and a slow acetylator phenotype. N-acetyltransferase phenotype was determined in 71 bladder cancer patients and in 74 control subjects from Copenhagen. The distribution of the slow acetylator phenotype among the bladder cancer patients was 65% in control to 51% among the control subjects, indicating that the N-acetyltransferase phenotype also in humans may be a determinant of the susceptibility of each individual to arylamine carcinogens. In addition, this finding indicates that carcinogenic arylamines also play a role in bladder carcinogenesis in Copenhagen. Such studies may identify risk groups in a population and may reveal geographical areas with arylamine induced bladder cancer.
Key concepts: Arylamine N-acetyltransferase, Carcinogen, Phenotype, N-acetyltransferase, Acetyltransferase, Bladder cancer, Carcinogenesis, Medicine